title: Immediate colposcopy or cytological surveillance for women with mild dyskaryosis: a cost effectiveness analysis.
abstract: BACKGROUND
  The aim of the study was to compare the cost effectiveness of immediate diagnosis and treatment of mild dyskaryosis compared with the usual policy of cytological surveillance.
  
  
  METHODS
  A cost effectiveness analysis was carried out alongside a randomized clinical trial.
  
  
  RESULTS
  Immediate diagnosis and treatment increased total costs by 50 per cent from 54.42 pounds per treated woman [95 per cent confidence interval (CI) 48.85 pounds-59.98 pounds] in the surveillance group to 82.02 pounds per woman in the immediate diagnosis and treatment group with an incremental cost of 27.60 pounds (95 per cent CI 22.04 pounds-33.17 pounds). However, the number of cases of CIN III detected increased by 69 per cent for the policy of immediate diagnosis and treatment. This led to an average cost effectiveness ration of 180.18 pounds for the immediate diagnosis and treatment group and 199.94 pounds per case of CIN III detected for the surveillance group, with a marginal cost effectiveness ratio of 148.22 pounds (95 per cent CI 94.01 pounds-309.33 pounds) for the immediate diagnosis and treatment group.
  
  
  CONCLUSIONS
  Immediate diagnosis and treatment increases the total cost of managing mildly dyskaryotic smears but this increased cost is offset by a sharp increase in the number of cases of CIN III detected.
authors.affiliation: Department of Obstetrics and Gynaecology, Aberdeen Royal Infirmary, Foresterhill.
authors.forename: G
authors.initials: G
authors.lastname: Flannelly
authors.forename: M K
authors.initials: MK
authors.lastname: Campbell
authors.forename: P
authors.initials: P
authors.lastname: Meldrum
authors.forename: D J
authors.initials: DJ
authors.lastname: Torgerson
authors.forename: A
authors.initials: A
authors.lastname: Templeton
authors.forename: H C
authors.initials: HC
authors.lastname: Kitchener
mesh_terms: D003127:Colposcopy / Q000191:economics*; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D006113:United Kingdom; D002578:Uterine Cervical Dysplasia / Q000175:diagnosis / Q000191:economics* / Q000628:therapy; D014626:Vaginal Smears / Q000191:economics*